Last updated: November 4, 2026
REXULTI, the brand name for brexpiprazole, has developed from an atypical antipsychotic for schizophrenia and adjunctive major depressive disorder into a broader neuropsychiatric franchise. Its 2023 FDA approval for agitation associated with Alzheimer’s dementia materially expanded the addressable market. U.S. sales growth remains supported by the Alzheimer’s indication, while long-term valuation depends on patent durability, generic litigation, payer management, and the ability of Otsuka and Lundbeck to defend premium pricing.
As of the end of 2024, REXULTI remained a commercially significant product with no publicly established generic launch in the United States. It is a small-molecule product, so its principal post-exclusivity threat is abbreviated new drug application, or ANDA, competition rather than biosimilar substitution.
What is REXULTI and who commercializes brexpiprazole?
REXULTI is brexpiprazole, an oral dopamine D2 and serotonin 5-HT1A partial agonist with serotonin 5-HT2A antagonist activity. Otsuka Pharmaceutical and H. Lundbeck A/S developed the product under a global collaboration.
| Item |
Detail |
| Active ingredient |
Brexpiprazole |
| Brand |
REXULTI |
| Drug class |
Atypical antipsychotic |
| Dosage form |
Oral tablets |
| U.S. sponsors |
Otsuka Pharmaceutical and Lundbeck |
| Initial FDA approval |
July 2015 |
| Initial indications |
Schizophrenia; adjunctive treatment of major depressive disorder |
| Expanded indication |
Agitation associated with Alzheimer’s dementia, approved May 2023 |
| Regulatory pathway |
New drug application |
| Generic pathway |
ANDA, not biosimilar |
| Primary commercial markets |
United States, Japan, Europe, and selected international markets |
The Alzheimer’s agitation indication was the principal strategic expansion. The FDA approval was based on two positive placebo-controlled studies in patients with probable Alzheimer’s dementia experiencing agitation. The label includes a boxed warning concerning increased mortality in elderly patients with dementia-related psychosis and a cerebrovascular adverse-event warning. REXULTI is not approved for dementia-related psychosis itself. [1]
How has REXULTI revenue changed over time?
REXULTI has moved from launch-stage antipsychotic to a multibillion-yen and multibillion-kroner global product. Reported figures vary because Otsuka and Lundbeck record revenue by geography and accounting arrangement rather than publishing one fully consolidated REXULTI number.
| Period |
Commercial development |
Financial interpretation |
| 2015-2017 |
U.S. launch in schizophrenia and adjunctive MDD |
Market adoption depended on differentiation from aripiprazole and other generic antipsychotics |
| 2018-2020 |
Expansion in depression augmentation and international markets |
Higher prescription volume offset intense competition in the broader antipsychotic category |
| 2021-2022 |
Continued U.S. growth |
Product became an important Lundbeck growth contributor |
| 2023 |
FDA approval for Alzheimer’s agitation |
New indication created a second major growth vector |
| 2024 |
Wider commercial rollout of Alzheimer’s indication |
Revenue growth remained positive, but payer controls and safety warnings constrained penetration |
Lundbeck has reported REXULTI revenue in the approximate range of DKK 3.8 billion for 2023 and DKK 4.4 billion for 2024, based on its annual-report product disclosures. Otsuka reports its share through its pharmaceutical segment and Japanese accounting disclosures. The two figures should not be added mechanically because each company reports different geographic and contractual portions of the product’s economics. [2][3]
The product’s combined global sales are generally understood to be above US$1 billion annually, with the United States representing the dominant market. The Alzheimer’s agitation label provides the main source of incremental growth because the schizophrenia and MDD markets are more mature and exposed to generic alternatives in competing therapies.
What drives REXULTI market growth?
Four factors determine the product’s commercial trajectory.
Alzheimer’s agitation expands the treated population
Agitation is common in Alzheimer’s dementia and has limited FDA-approved pharmacologic treatment options. The 2023 approval allows physicians to prescribe REXULTI for a defined symptom domain rather than relying solely on off-label antipsychotic use.
The opportunity is large, but the eligible commercial population is narrower than the overall Alzheimer’s population. Treatment is generally directed at patients with clinically significant agitation after nonpharmacologic interventions and risk assessment. The boxed warning limits use and affects prescriber behavior.
REXULTI benefits from a differentiated commercial position
In depression, REXULTI competes with generic antidepressants and other adjunctive agents, including generic aripiprazole. Its commercial value depends on tolerability, physician familiarity, formulary access, and persistence.
Compared with aripiprazole, brexpiprazole is generally positioned as having lower akathisia risk in some clinical settings, although comparative treatment decisions remain patient-specific. That positioning supports premium pricing but does not eliminate payer pressure.
The product has multiple indications
A multi-indication label reduces dependence on one specialty market. Schizophrenia supports psychiatry demand, MDD supports primary-care and psychiatric augmentation, and Alzheimer’s agitation adds neurology, geriatrics, and memory-care demand.
The same breadth also creates regulatory and commercial constraints. The dementia indication carries heightened safety scrutiny, and broad antipsychotic class warnings limit promotional flexibility.
Commercial infrastructure supports durable prescribing
Otsuka and Lundbeck have established relationships with psychiatric prescribers, hospitals, specialty pharmacies, and managed-care organizations. The companies can use the existing REXULTI infrastructure to support the Alzheimer’s launch without building an entirely new commercial platform.
What is the FDA regulatory status of REXULTI?
REXULTI is fully approved in the United States for three principal uses:
- Treatment of schizophrenia in adults.
- Adjunctive treatment of major depressive disorder in adults.
- Treatment of agitation associated with dementia due to Alzheimer’s disease.
The Alzheimer’s approval is commercially important but carries the most substantial regulatory risk. The FDA label states that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. REXULTI is not approved for dementia-related psychosis, and the label prohibits treating that broader condition under the Alzheimer’s agitation approval. [1]
The product is not a biologic. Biosimilar substitution is therefore not relevant. The relevant future competition is generic brexpiprazole under the ANDA pathway.
What patents protect REXULTI?
REXULTI’s U.S. patent estate has included composition-of-matter, chemical-structure, formulation, and method-of-use protection. Public patent records associate key brexpiprazole protection with Otsuka and related entities.
| Protection category |
Representative U.S. patent |
Commercial relevance |
| Core brexpiprazole compound and chemical class |
U.S. Patent No. 7,888,362 |
Principal early composition protection |
| Additional compound or therapeutic claims |
U.S. Patent No. 8,338,486 |
Supports protection beyond the earliest compound patent |
| Solid-state, formulation, or therapeutic-use claims |
Later Otsuka patents and Orange Book-listed continuations |
Can delay or complicate generic approval |
| Alzheimer’s agitation use |
Later method-of-use protection associated with the expanded indication |
Protects the approved use, not necessarily all brexpiprazole sales |
The earliest core patent protection is generally associated with expiration in the 2026-2027 period, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the exact claims asserted. Later patents can extend protection for specific formulations or approved uses into the late 2020s or beyond, but they do not necessarily block a generic from entering for every indication.
The FDA Orange Book is the controlling source for current listed patents, pediatric exclusivity, and the expiration information used in ANDA certification analysis. Patent listings can change as sponsors add, delist, or correct patents. [4]
When does REXULTI lose exclusivity?
REXULTI’s effective loss-of-exclusivity date depends on three separate events:
| Exclusivity layer |
Expected timing |
Impact |
| Core compound patent protection |
Approximately 2026-2027 |
Highest risk of broad generic entry |
| Later formulation and method patents |
Approximately 2028-2035, depending on patent and claim |
May preserve selected uses or delay launches |
| FDA regulatory exclusivity for Alzheimer’s agitation |
Limited period associated with the 2023 approval |
Does not independently create long-term market protection |
The core risk is a generic applicant that certifies Paragraph IV against listed patents and wins, settles, or otherwise resolves the resulting litigation. Later method-of-use patents may allow a skinny-label generic that excludes the Alzheimer’s indication while entering for schizophrenia and MDD.
A patent expiry date does not automatically equal a full-market generic launch date. Commercial entry may be delayed by litigation, settlement terms, manufacturing readiness, FDA approval timing, controlled-distribution requirements, or the economic value of launching at risk.
Which companies are challenging REXULTI patents?
Publicly identified ANDA challengers and litigation details have not produced a single confirmed generic launch date for brexpiprazole through the end of 2024. Generic companies commonly involved in large CNS-product challenges include Teva, Lupin, Zydus, Alembic, Hetero, and related applicants, but the identity of a challenger must be tied to a specific court docket or FDA Paragraph IV notice before it is treated as confirmed.
A Paragraph IV certification means that an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. The sponsor may file a patent-infringement action within 45 days, triggering a statutory stay of FDA approval that can last up to 30 months, subject to court action and statutory exceptions. [5]
The most consequential litigation question is whether challengers attack the core compound claims or only later formulation and method-of-use patents. A successful challenge to the core compound claims would create broad entry risk. A successful challenge limited to a use patent could leave branded REXULTI sales intact in protected indications while permitting a generic for nonprotected uses.
What formulation and method-of-use patents protect REXULTI?
Formulation patents can cover dosage strengths, solid forms, particle characteristics, excipients, dissolution profiles, or manufacturing processes. Method-of-use patents can cover treatment of specific disorders or patient populations.
For REXULTI, the most commercially important later-use protection is associated with agitation in Alzheimer’s dementia. Its value depends on whether a generic product can enter with a label that omits the protected indication and whether pharmacists, payers, and prescribers keep the generic effectively confined to nonprotected uses.
Formulation patents are usually weaker than valid composition patents because their enforceability depends on claim scope, prosecution history, obviousness, and the ability of a generic manufacturer to design around the claims. They can still delay entry when combined with a statutory stay or settlement restriction.
What generic launch scenarios exist for REXULTI?
Scenario 1: Broad launch after core patent loss
A generic enters for all or most REXULTI strengths after defeating or resolving core patents. Price erosion could be substantial, particularly in schizophrenia and MDD, where physicians are accustomed to generic antipsychotic treatment.
Scenario 2: Skinny-label launch
A generic launches for schizophrenia and MDD but excludes Alzheimer’s agitation. This would preserve some branded dementia revenue while exposing the mature indications to rapid substitution.
Scenario 3: Negotiated delayed entry
Otsuka, Lundbeck, and generic applicants settle litigation with a defined entry date. The settlement could include limited use rights, patent-license terms, or restrictions associated with particular patents. Public assessment must rely on filed agreements and FTC review where applicable. [6]
Scenario 4: Litigation-driven delay
The branded companies prevail on one or more patents, or a court maintains a stay through the relevant approval period. This scenario extends exclusivity but increases litigation expense and does not eliminate later entry risk.
How strong is the REXULTI patent estate?
The estate is commercially meaningful but not uniformly strong.
| Factor |
Assessment |
| Core compound protection |
Strongest protection, but earliest expiration creates a defined cliff |
| Multiple indications |
Positive for lifecycle management and revenue retention |
| Alzheimer’s method patenting |
Potentially valuable, but vulnerable to skinny-label strategies |
| Formulation patents |
Moderate value; subject to design-around and validity challenges |
| Patent-term timing |
Critical because later patents may not block all indications |
| Regulatory exclusivity |
Helpful for launch support but not a substitute for durable patent protection |
| Litigation exposure |
Material through the first broad generic challenge |
The strongest defense is the combination of high prescription volume, multiple indications, later-use claims, and commercial execution. The principal weakness is that the molecule is a small-molecule oral tablet with a foreseeable generic pathway. Once broad generic brexpiprazole becomes available, brand retention will depend on clinical preference, payer contracts, patient stability, and rebate economics.
How does REXULTI compare with competing antipsychotics?
| Product |
Active ingredient |
Generic status |
Key commercial difference |
| REXULTI |
Brexpiprazole |
Branded through the relevant exclusivity period |
MDD augmentation and Alzheimer’s agitation indications |
| ABILIFY |
Aripiprazole |
Generic available |
Broad clinical history and low-cost competition |
| VRAYLAR |
Cariprazine |
Branded |
Competes in schizophrenia, bipolar disorder, and MDD |
| LATUDA |
Lurasidone |
Generic available |
Strong historical bipolar and schizophrenia presence |
| CAPLYTA |
Lumateperone |
Branded |
Competes in schizophrenia, bipolar depression, and MDD |
| SEROQUEL XR |
Quetiapine extended release |
Generic competition |
Established use but heavy price pressure |
REXULTI’s competitive advantage is the combination of adjunctive MDD adoption and the FDA-approved Alzheimer’s agitation indication. Its main disadvantage is premium pricing against generic aripiprazole and other low-cost alternatives.
What revenue exposure exists after generic entry?
The Alzheimer’s indication is likely to be the most valuable protection for the late-life revenue curve, assuming the branded companies maintain effective indication-specific promotion and payer differentiation. Schizophrenia and MDD sales are more exposed to broad generic substitution once core patents expire.
A likely revenue pattern is:
- Continued growth during Alzheimer’s indication expansion.
- Slower growth as formulary restrictions and safety concerns moderate uptake.
- Initial erosion after broad generic approval.
- Faster decline in mature indications than in protected or clinically differentiated use.
- Residual branded revenue from dementia care, stable patients, and prescribers who prefer the branded product.
The scale of erosion will depend on the number of first-wave entrants. One or two generic entrants can preserve meaningful prices temporarily. A crowded generic field usually produces much faster price compression.
What licensing deals support REXULTI?
Otsuka and Lundbeck operate under a long-standing collaboration covering development and commercialization of brexpiprazole. The agreement gives Lundbeck substantial commercial participation outside Japan and reflects the partners’ shared development history.
The agreement is strategically important because it aligns global commercialization, regulatory submissions, and lifecycle management. It also means revenue and profit exposure is divided between the companies rather than reported by a single manufacturer. Public annual reports provide product and segment revenue, but they do not always disclose the complete product-level economics of every territory. [2][3]
Key Takeaways
- REXULTI is brexpiprazole, a small-molecule atypical antipsychotic marketed by Otsuka and Lundbeck.
- The 2023 Alzheimer’s agitation approval created the product’s principal new growth opportunity.
- Global REXULTI revenue is above the billion-dollar scale, with Lundbeck reporting approximately DKK 3.8 billion in 2023 and DKK 4.4 billion in 2024.
- Core patent protection is generally associated with the 2026-2027 period, while later formulation and method patents may extend selected protection into the late 2020s or beyond.
- Generic risk is based on ANDA Paragraph IV litigation, not biosimilar competition.
- A skinny-label generic could enter schizophrenia and MDD while leaving Alzheimer’s agitation subject to separate method-of-use protection.
- The patent estate is commercially useful but cannot guarantee protection against broad generic entry after core compound expiry.
- Revenue exposure is highest in mature schizophrenia and MDD uses and potentially lower in the newer Alzheimer’s agitation market.
FAQs About REXULTI Patent Expiration and Market Competition
Is REXULTI a biologic or a small-molecule drug?
REXULTI is a small-molecule drug. Generic manufacturers can seek approval through the ANDA pathway. Biosimilar regulation does not apply.
Does REXULTI have an Alzheimer’s disease approval?
REXULTI is approved for agitation associated with dementia due to Alzheimer’s disease. It is not approved to treat Alzheimer’s dementia itself or dementia-related psychosis generally.
Can generic brexpiprazole launch before every REXULTI patent expires?
Potentially. An ANDA applicant may certify that a patent is invalid, unenforceable, or not infringed. A court decision, settlement, or skinny-label strategy can permit entry before every listed patent expires.
Why is the Alzheimer’s indication important to REXULTI valuation?
It expands the product into a large patient population with limited approved pharmacologic options. It also supports lifecycle management after the schizophrenia and MDD markets mature.
What is the main financial risk to Otsuka and Lundbeck?
The main risk is broad generic entry after core compound protection expires. Generic substitution could rapidly reduce price and volume in schizophrenia and MDD, while later-use patents may protect only part of the Alzheimer’s-related revenue.
References
- U.S. Food and Drug Administration. (2023). REXULTI (brexpiprazole) prescribing information.
- H. Lundbeck A/S. (2024). Annual report 2024.
- Otsuka Holdings Co., Ltd. (2024). Integrated report and financial results materials.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
- Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act.